DOCSLIB.ORG

Assessment of Anandamide's Pharmacological Effects in Mice Deficient of Both Fatty Acid Amide Hydrolase and Cannabinoid CB1 Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assessment of Anandamide's Pharmacological Effects in Mice Deficient of Both Fatty Acid Amide Hydrolase and Cannabinoid CB1 Receptors European Journal of Pharmacology 557 (2007) 44–48 www.elsevier.com/locate/ejphar Short communication Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors Laura E. Wise a, Christopher C. Shelton a, Benjamin F. Cravatt b, ⁎ Billy R. Martin a, Aron H. Lichtman a, a Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298-0613, United States b The Skaggs Institute for Chemical Biology and Departments of Cell Biology and Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd. La Jolla, CA 92037, United States Received 12 September 2006; received in revised form 2 November 2006; accepted 6 November 2006 Available online 10 November 2006 Abstract In the present study, we investigated whether anandamide produces its behavioral effects through a cannabinoid CB1 receptor mechanism of action. The behavioral effects of anandamide were evaluated in mice that lacked both fatty acid amide hydrolase (FAAH) and cannabinoid CB1 receptors (DKO) as compared to FAAH (−/−), cannabinoid CB1 (−/−), and wild type mice. Anandamide produced analgesia, catalepsy, and hypothermia in FAAH (−/−) mice, but failed to elicit any of these effects in the other three genotypes. In contrast, anandamide decreased locomotor behavior regardless of genotype, suggesting the involvement of multiple mechanisms of action, including its products of degradation. These findings indicate that the cannabinoid CB1 receptor is the predominant target mediating anandamide's behavioral effects. © 2006 Elsevier B.V. All rights reserved. Keywords: Cannabinoid CB1 receptor; FAAH [Fatty acid amide hydrolase]; N-arachidonoyl ethanolamine (anandamide); Pain; Analgesia; Marijuana 1. Introduction 1998a,b; Smith et al., 1998, 1994). Thus, anandamide's weak and transient pharmacological effects in mice (Smith et al., 1994), While anandamide is most prominently known as the first rats (Lichtman et al., 1996), and dogs (Lichtman et al., 1998)after endogenous cannabinoid extracted from mammalian brain, it has exogenous administration is not altogether surprising. CB1 (−/−) activity at multiple targets including cannabinoid CB1 receptors, mice as well as mice pretreated with the cannabinoid CB1 re- cannabinoid CB2 receptors (Calignano et al., 1998; Sokal et al., ceptor antagonist rimonabant exhibit pharmacological effects 2003), TRPV1 receptors (Tognetto et al., 2001; Zygmunt et al., following intravenously injected anandamide, suggesting a non- 1999), potassium channels (Maingret et al., 2001), T-type calci- CB1 receptor mechanism of action (Adams et al., 1998; Di Marzo um channels (Chemin et al., 2001), and gap junctions (Venance et al., 2000; Smith et al., 1994). In contrast, anandamide given et al., 1995). The rapid catabolism and consequent short half-life through the intraperitoneal route of administration to either (Willoughby et al., 1997) of this lipid signaling molecule by fatty FAAH (−/−) mice or mice treated with FAAH inhibitors elicits acid amide hydrolase (FAAH) have undoubtedly contributed to profound pharmacological effects, which are blocked by discrepant findings from various investigations in whole ani- SR141716 (Cravatt et al., 2001, 2004; Kathuria et al., 2003; mals.(Adams et al., 1998; Calignano et al., 1998; Costa et al., Lichtman et al., 2004). Of course, a major difference between the 1999; Di Marzo et al., 2000; Farquhar-Smith and Rice, 2001; two strategies is that high doses of anandamide were required to Jaggar et al., 1998; Lichtman et al., 1996; Richardson et al., elicit a pharmacological effect in wild type mice and consid- erable quantities of metabolites are formed, whereas low doses of anandamide can produce pharmacological effects in FAAH − − ⁎ Corresponding author. Tel.: +1 804 828 8480. ( / ) mice. While products of metabolism could contribute to E-mail address: [email protected] (A.H. Lichtman). anandamide's effects in the wild type animals, it remains 0014-2999/$ - see front matter © 2006 Elsevier B.V. All rights reserved. doi:10.1016/j.ejphar.2006.11.002 L.E. Wise et al. / European Journal of Pharmacology 557 (2007) 44–48 45 plausible that the effects of this endogenous cannabinoid are laboratory have previously shown that at 52 °C there are no mediated through a non-CB1 receptor mechanism of action. genotype differences in baseline hotplate latencies among The purpose of the present study was to investigate whether FAAH (+/+), (+/−), or (−/−) mice (Cravatt et al., 2001; Lichtman intact anandamide produces overt behavioral effects at sites et al., 2004). Rectal temperature was determined using a tele- other than cannabinoid CB1 receptors. In order to address this thermometer by inserting a thermocouple probe 2.0 cm into the question, we created mice that lacked both FAAH and canna- rectum. Following baseline assessments, each subject was given binoid CB1 receptor genes (DKO mice) by selectively breeding an i.p. injection of vehicle or 50 mg/kg anandamide. The mice FAAH (−/−) mice with CB1 (+/−) mice. We then investigated the were then placed into photocell activity cages (6.5×11 in.) effects of anandamide in DKO mice as compared to wild type, where locomotor activity was assessed from 10–20 min post- CB1 (−/−), and FAAH (−/−) mice in the tetrad test, a well injection by recording the total number of photocell beam in- established screen for cannabinoid activity (Compton et al., terruptions (Omnitech Electronics Inc., Columbus, OH). Imme- 1990, 1993; Martin et al., 1991). diately after locomotor activity assessment, hot plate latencies were evaluated. Catalepsy and rectal temperature were deter- 2. Methods mined 60 min post-injection (Cravatt et al., 2001; Lichtman et al., 2004). Catalepsy was determined using the bar test, in 2.1. Subjects which the front paws of each subject were placed on a rod (0.75 cm diameter) that was elevated 4.5 cm from the bench top. The subjects consisted of male and female mice on a C57BL/ The duration of time that the mice remained motionless (with the 6 background of the following four genotypes: 1) wild type: exception of respiratory movements) with their front paws on the FAAH (+/−)/CB1 (+/+); 2) CB1 (−/−) mice: FAAH (+/−)/CB1 bar for 10 s was scored. The same subjects were evaluated (−/−); 3) FAAH (−/−) mice: FAAH (−/−)/CB1 (+/−); and 4) following vehicle and anandamide administration in a counter- DKO: FAAH (−/−)/CB1 (−/−). Previous studies have demon- balanced fashion with at least 72 h between test days to control strated that FAAH (+/−) mice display virtually identical phe- for any order effects. notypes as wild type mice (Cravatt et al., 2001, 2004; Lichtman et al., 2004) and thus were used as a control in this study. All 2.4. Data analysis subjects were littermates derived from FAAH (−/−)/CB1 (+/−) and FAAH (+/−)/CB1 (+/−) breeding pairs. These breeding pairs Two-way analysis of variance (ANOVA) was used to eval- yielded a greater percentage of the desired genotypes for these uate whether baseline hot plate and body temperatures differed experiments than had the breeding pairs consisted of two mice among the four genotypes (CB1 vs. FAAH) and three-way with FAAH (+/−)/CB1 (+/−) genotypes. All mice were born ANOVA was used to analyze drug differences among the four in the Virginia Commonwealth University vivarium. Subjects genotypes (anandamide vs. CB1 vs. FAAH) in each assay. weighed between 18 and 30 g, and were housed four to five Scheffe test was used for post-hoc analyses. Differences were animals per cage in a temperature-controlled (20–22 °C) facility. considered significant at the Pb0.05 level. Mice were given unlimited access to food and water and were maintained on a 12/12-h light/dark cycle. The Institutional 3. Results Animal Care and Use Committee at Virginia Commonwealth University approved all experiments. No relevant differences were found among the different genotypes with respect to baseline hot plate latencies or body 2.2. Drugs temperatures (Table 1), though mice lacking cannabinoid CB1 receptors displayed a small, but a significant decrease in baseline Anandamide was synthesized as previously described rectal temperature, F(1, 39)=7.6, Pb0.01. Significant three- (Cravatt et al., 1996). The vehicle consisted of a mixture of way interactions were found among FAAH genotype, CB1 ge- ethanol:alkamuls-620 (Rhone-Poulenc, Princeton, NJ):saline in notype, and anandamide for analgesia (F(1,39)=37, Pb0.001), a ratio of 1:1:18, respectively. Mice were given an i.p. injection catalepsy (F(1,39)=10, Pb0.01), and hypothermia (F(1,39)= of vehicle or anandamide (50 mg/kg) in a volume of 10 μl/g body 26, Pb0.001). As shown in Fig. 1, anandamide elicited anal- weight. This dose of anandamide was previously found to pro- gesia, catalepsy, and hypothermia in FAAH (−/−)/CB1 (+/+) duce profound pharmacological effects in FAAH (−/−), but not in (+/−) or (+/+), mice (Cravatt et al., 2001, 2004; Lichtman et al., 2004) and, thus, was used in the present study to assess Table 1 anandamide's effects in each of the four genotypes. Baseline hot plate latencies and rectal temperatures FAAH CB1 Hot plate latency Rectal temperature n 2.3. Behavioral measures genotype genotype (s) (°C) +/− +/+ 16.8±1.5 36.1±0.1 12 Subjects were assessed for basal responses in the hot plate test +/−−/− 17.9±1.5 35.9±0.1 12 and baseline rectal temperature. The hot plate that was main- −/− +/+ 17.2±1.8 36.1±0.1 12 tained at 52 °C, and the latency to jump or lick/shake a hind paw −/−−/− 16.5±1.9 35.6±0.2 7 within a 60 s observation period was recorded. Results from our All values reflect mean±S.E.M. 46 L.E. Wise et al. / European Journal of Pharmacology 557 (2007) 44–48 Fig. 1. The effect of anandamide (50 mg/kg, open bars) on locomotor activity (A), the hot plate test (B), the bar test (C), and body temperature (D) in FAAH (+/−)/CB1 (+/+) (n=12), FAAH (+/−)/CB1 (−/−)(n=12), FAAH (+/−)/CB1 (+/−)(n=12), and FAAH (−/−)/CB1 (−/−)(n=7) mice.
Load more

Recommended publications
  • Modulation of Central Endocannabinoid System Results in Gastric Mucosal Protection in the Rat
    Modulation of central endocannabinoid system results in gastric mucosal protection in the rat Tóth, V.E.1, Fehér, Á.1, Németh, J.2, Gyertyán, I.3, Zádori, Z.S.1, Gyires K.1 1 Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary; 2 Department of Pharmacology and Pharmacotherapy, University of Debrecen, Nagyerdei krt. 98., 4032 Debrecen, Hungary; 3 MTA-SE NAP B Cognitive Translational Behavioural Pharmacology Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary *Corresponding author: Klára Gyires Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad tér 4., 1089, Budapest, Hungary Phone: 36-1-210-4416, Fax: 36-1-210-4412 e-mail: [email protected] 1 Abstract Previous findings showed that inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), degrading enzymes of anandamide (2-AEA) and 2- arachidonoylglycerol (2-AG), reduced the nonsteroidal anti-inflammatory drug-induced gastric lesions. The present study aimed to investigate: i./whether central or peripheral mechanism play a major role in the gastroprotective effect of inhibitors of FAAH, MAGL and AEA uptake, ii./ which peripheral mechanism(s) may be responsible for mucosal protective effect of FAAH, MAGL and uptake inhibitors. Methods: Gastric mucosal damage was induced by acidified ethanol. Gastric motility was measured in anesthetized rats. Catalepsy and the body temperature were also evaluated. Mucosal calcitonin gene- related peptide (CGRP), somatostatin concentrations and superoxide dismutase (SOD) activity were measured. The compounds were injected intraperitoneally (i.p.) or intracerebroventricularly (i.c.v.). Results: 1. URB 597, JZL184 (inhibitors of FAAH and MAGL) and AM 404 (inhibitor of AEA uptake) decreased the mucosal lesions significantly given either i.c.v.
    [Show full text]
  • The Selective Reversible FAAH Inhibitor, SSR411298, Restores The
    www.nature.com/scientificreports OPEN The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive Received: 22 September 2017 Accepted: 26 January 2018 behaviors to acute and chronic Published: xx xx xxxx stress in rodents Guy Griebel1, Jeanne Stemmelin2, Mati Lopez-Grancha3, Valérie Fauchey3, Franck Slowinski4, Philippe Pichat5, Gihad Dargazanli4, Ahmed Abouabdellah4, Caroline Cohen6 & Olivier E. Bergis7 Enhancing endogenous cannabinoid (eCB) signaling has been considered as a potential strategy for the treatment of stress-related conditions. Fatty acid amide hydrolase (FAAH) represents the primary degradation enzyme of the eCB anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This study describes a potent reversible FAAH inhibitor, SSR411298. The drug acts as a selective inhibitor of FAAH, which potently increases hippocampal levels of AEA, OEA and PEA in mice. Despite elevating eCB levels, SSR411298 did not mimic the interoceptive state or produce the behavioral side-efects (memory defcit and motor impairment) evoked by direct-acting cannabinoids. When SSR411298 was tested in models of anxiety, it only exerted clear anxiolytic-like efects under highly aversive conditions following exposure to a traumatic event, such as in the mouse defense test battery and social defeat procedure. Results from experiments in models of depression showed that SSR411298 produced robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress. This preclinical profle positions SSR411298 as a promising drug candidate to treat diseases such as post-traumatic stress disorder, which involves the development of maladaptive behaviors. Te endocannabinoid (eCB) system is formed by two G protein-coupled receptors, CB1 and CB2, and their main transmitters, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoyglycerol (2-AG)1.
    [Show full text]
  • The Endocannabinoid System and Harm Reduc on with Cannabis
    The Endocannabinoid System and Harm Reduc6on with Cannabis Gregory Gerdeman, PhD Mary Lynn Mathre, RN, MSN, CARN Cannabis is real medicine • Cannabis is safe medicine • Studying cannabis led to discovery of the Ethan Russo, MD ENDOCANNABINOID SYSTEM (ECS) • Cannabinoid receptors (acvated by THC) • Endogenous THC-like cannabinoid signaling molecules (endocannabinoids) • Endocannabinoid metabolic enzymes • ECS is a “master regulator” of human physiology Effects of cannabis in the brain are undeniably the root of human aOracGon and aversion – both – to this plant that has been culvated and ulized as medicine for longer than any historical record. A Gmeline of major discoveries in the research of cannabis and the cannabinoids 1964 – Gaoni and Mechoulam isolate Δ9-THC from hashish 1980’s – “Tetrad” test of cannabinoid effects is developed, and used to test syntheGc analogs. 1988 – CB1 cannabinoid receptor is idenGfied. 1992 – Anandamide is discovered as first endocannabinoid The focus of cannabis research in the 2nd half of the 20th century was not so even-handed. • How does marijuana make someone… • Stoned Led to … The • Lazy endocannabinoid • Addicted (including to other drugs) system • Violent!!! • Mentally impaired for life… brain damage model (THC as neurotoxin) • Insane (paranoid schizophrenia) Mainstream scienGfic concepGons of the endocannabinoid system are now well beyond the exclusive domain of drug abuse research … Endocannabinoid signaling as a synapGc circuit breaker in neurological disease István Katona & Tamás F Freund Nature Medicine,
    [Show full text]
  • Distinct Roles of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol in Social Behavior and Emotionality at Different Developmental Ages in Rats
    European Neuropsychopharmacology (2015) 25, 1362–1374 www.elsevier.com/locate/euroneuro Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats Antonia Manducaa, Maria Morenab,c, Patrizia Campolongob, Michela Servadioa, Maura Palmeryb, Luigia Trabaced, Matthew N. Hillc, Louk J.M.J. Vanderschurene,f, Vincenzo Cuomob, Viviana Trezzaa,n aDepartment of Science, Section of Biomedical Sciences and Technologies, University “Roma Tre”, Rome, Italy bDepartment of Physiology and Pharmacology, Sapienza, University of Rome, Rome, Italy cHotchkiss Brain Institute, Departments of Cell Biology and Anatomy and Psychiatry, University of Calgary, Calgary, AB, Canada dDepartment of Clinical and Experimental Medicine, Faculty of Medicine, University of Foggia, Foggia, Italy eDepartment of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands fDepartment of Animals in Science and Society, Division of Behavioural Neuroscience, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands Received 30 November 2014; received in revised form 25 February 2015; accepted 1 April 2015 KEYWORDS Abstract Endocannabinoid sys- To date, our understanding of the relative contribution and potential overlapping roles of the tem; endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in the regulation of Social behavior; brain function and behavior is still limited. To address this issue, we investigated the effects of Endocannabinoids; systemic administration of JZL195, that simultaneously increases AEA and 2-AG signaling by Emotional behavior; inhibiting their hydrolysis, in the regulation of socio-emotional behavior in adolescent and Rodents; adult rats. JZL195 JZL195, administered at the dose of 0.01 mg/kg, increased social play behavior, that is the most characteristic social activity displayed by adolescent rats, and increased social interaction in adult animals.
    [Show full text]
  • (THC) and Cannabidiol (CBD) in Male and Female Rats: Sex, Dose-Effec
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.11.443601; this version posted May 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations Catherine F. Moore*, Elise M. Weerts Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD ∗ Corresponding author at: Johns Hopkins Bayview Research Campus, Behavioral Biology Research Center, 5510 Nathan Shock Drive, Suite 3000, Baltimore, MD 21224, USA. E-mail address: [email protected]. Tel: (410) 550-4316, Fax: (410) 550-0030. Acknowledgements All experiments were supported by the National Institute on Drug Abuse of the National Institutes of Health grant numbers R21DA046154 (EW) and the Johns Hopkins University Dalio Fund in Decision Making and the Neuroscience of Motivated Behaviors (EW). The authors have no conflicts of interest to disclose. 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.11.443601; this version posted May 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Rationale The legalization of medicinal use of Cannabis sativa in most US states and the removal of hemp from the Drug Enforcement Agency (DEA) controlled substances act has resulted in a proliferation of products containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for oral consumption (e.g., edibles, oils and tinctures) that are being used for recreational and medicinal purposes.
    [Show full text]
  • Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling
    International Journal of Molecular Sciences Review Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling Kenneth B. Walsh * and Haley K. Andersen Department of Pharmacology, Physiology & Neuroscience, University of South Carolina, School of Medicine, Columbia, SC 29208, USA; [email protected] * Correspondence: [email protected] Received: 24 July 2020; Accepted: 14 August 2020; Published: 25 August 2020 Abstract: Synthetic cannabinoids (SCs) are a class of new psychoactive substances (NPSs) that exhibit high affinity binding to the cannabinoid CB1 and CB2 receptors and display a pharmacological profile similar to the phytocannabinoid (-)-trans-D9-tetrahydrocannabinol (THC). SCs are marketed under brand names such as K2 and Spice and are popular drugs of abuse among male teenagers and young adults. Since their introduction in the early 2000s, SCs have grown in number and evolved in structural diversity to evade forensic detection and drug scheduling. In addition to their desirable euphoric and antinociceptive effects, SCs can cause severe toxicity including seizures, respiratory depression, cardiac arrhythmias, stroke and psychosis. Binding of SCs to the CB1 receptor, expressed in the central and peripheral nervous systems, stimulates pertussis toxin-sensitive G proteins (Gi/Go) resulting in the inhibition of adenylyl cyclase, a decreased opening of N-type Ca2+ channels and the activation of G protein-gated inward rectifier (GIRK) channels. This combination of signaling effects dampens neuronal activity in both CNS excitatory and inhibitory pathways by decreasing action potential formation and neurotransmitter release. Despite this knowledge, the relationship between the chemical structure of the SCs and their CB1 receptor-mediated molecular actions is not well understood.
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacol Biochem Behav
    NIH Public Access Author Manuscript Pharmacol Biochem Behav. Author manuscript; available in PMC 2011 June 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Biochem Behav. 2010 June ; 95(4): 434±442. doi:10.1016/j.pbb.2010.03.004. Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Abir T. El-Alfya,*, Kelly Iveya, Keisha Robinsona, Safwat Ahmedb,1, Mohamed Radwanb, Desmond Sladeb, Ikhlas Khanb,c, Mahmoud ElSohlyb,d, and Samir Rossb,c a Pharmacology Department, School of Pharmacy, University of Mississippi, University, MS 38677, USA b National Center for Natural Products Research, University of Mississippi, University, MS 38677, USA c Pharmacognosy Department, School of Pharmacy, University of Mississippi, University, MS 38677, USA d Pharmaceutics Department, School of Pharmacy, University of Mississippi, University, MS 38677, USA Abstract The antidepressant action of cannabis as well as the interaction between antidepressants and the endocannabinoid system has been reported. This study was conducted to assess the antidepressant- like activity of Δ9-THC and other cannabinoids. Cannabinoids were initially evaluated in the mouse tetrad assay to determine doses that do not induce hypothermia or catalepsy. The automated mouse forced swim (FST) and tail suspension (TST) tests were used to determine antidepressant action. At doses lacking hypothermic and cataleptic effects (1.25, 2.5, and 5 mg/kg, i.p.), both Δ9-THC and Δ8-THC showed a U-shaped dose response with only Δ9-THC showing significant antidepressant- like effects at 2.5 mg/kg (p < 0.05) in the FST.
    [Show full text]
  • Dual Blockade of FAAH and MAGL Identifies Behavioral Processes Regulated by Endocannabinoid Crosstalk in Vivo
    Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Jonathan Z. Longa, Daniel K. Nomuraa, Robert E. Vannb, D. Matthew Walentinyb, Lamont Bookerb, Xin Jina, James J. Burstonb, Laura J. Sim-Selleyb, Aron H. Lichtmanb, Jenny L. Wileyb, and Benjamin F. Cravatta,1 aThe Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037; and bDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298-0613 Edited by Michael A. Marletta, University of California, Berkeley, CA, and approved October 6, 2009 (received for review August 19, 2009) ⌬9-Tetrahydrocannabinol (THC), the psychoactive component of mar- serve as key points of control over specific endocannabinoid ijuana, and other direct cannabinoid receptor (CB1) agonists produce signaling events in vivo (13). Fatty acid amide hydrolase (FAAH) a number of neurobehavioral effects in mammals that range from the is the major degradative enzyme for AEA (14–16). In contrast, beneficial (analgesia) to the untoward (abuse potential). Why, how- although several enzymes can hydrolyze 2-AG, this reaction ap- ever, this full spectrum of activities is not observed upon pharmaco- pears to be primarily catalyzed by monoacylglycerol lipase (MAGL) logical inhibition or genetic deletion of either fatty acid amide in the nervous system (17). The designation of FAAH and MAGL hydrolase (FAAH) or monoacylglycerol lipase (MAGL), enzymes that as principal AEA and 2-AG degradative enzymes, respectively, is regulate the two major endocannabinoids anandamide (AEA) and supported by a combination of genetic and pharmacological stud- 2-arachidonoylglycerol (2-AG), respectively, has remained unclear.
    [Show full text]
  • Npgrj Nchembio 129 1..8
    ARTICLES Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects y Jonathan Z Long1, Weiwei Li1, Lamont Booker3, James J Burston3, Steven G Kinsey3, Joel E Schlosburg3, Franciso J Pavo´n2, Antonia M Serrano2, Dana E Selley3, Loren H Parsons2, Aron H Lichtman3 & Benjamin F Cravatt1 2-Arachidonoylglycerol (2-AG) and anandamide are endocannabinoids that activate the cannabinoid receptors CB1 and CB2. Endocannabinoid signaling is terminated by enzymatic hydrolysis, a process that for anandamide is mediated by fatty acid amide hydrolase (FAAH), and for 2-AG is thought to involve monoacylglycerol lipase (MAGL). FAAH inhibitors produce a select subset of the behavioral effects observed with CB1 agonists, which suggests a functional segregation of endocannabinoid signaling pathways in vivo. Testing this hypothesis, however, requires specific tools to independently block anandamide and 2-AG metabolism. Here, we report a potent and selective inhibitor of MAGL called JZL184 that, upon administration to mice, raises brain 2-AG by eight-fold without altering anandamide. JZL184-treated mice exhibited a broad array of CB1-dependent behavioral effects, including analgesia, hypothermia and hypomotility. These data indicate that 2-AG endogenously modulates several behavioral processes classically associated with the pharmacology of cannabinoids and point to overlapping and unique functions for 2-AG and anandamide in vivo. http://www.nature.com/naturechemicalbiolog The cannabinoid receptors CB1 and CB2 are molecular targets for recombinant expression of MAGL reduces receptor-dependent 2-AG D9-tetrahydrocannabinol (1), the psychoactive component of mari- accumulation in cortical neurons18. Second, immunodepletion of juana1. Two endogenous ligands, or endocannabinoids, have also been MAGL decreases 2-AG hydrolysis activity in rat brain tissue by 50% identified: the arachidonate-based lipids anandamide (N-arachidonoy- (ref.
    [Show full text]
  • Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects
    International Journal of Molecular Sciences Article Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects 1, 2, 3 4 Qing-Rong Liu *, Ana Canseco-Alba y, Ying Liang , Hiroki Ishiguro and Emmanuel S. Onaivi 2,* 1 Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD 21224, USA 2 Department of Biology, William Paterson University, Wayne, NJ 07470, USA; [email protected] 3 College of Food Science and Engineering, Central South University of Forestry and Technology, Changsha 410004, Hunan, China; [email protected] 4 Department of Neuropsychiatry, Graduate School of Medical Science, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan; [email protected] * Correspondence: [email protected] (Q.-R.L.); [email protected] (E.S.O.) New address: Dirección de Investigación, Instituto Nacional de Neurología y Neurocirugía INNN, y Laboratorio de investigación en adicciones, La Fama, Tlalpan, Mexico City 14269, Mexico. Received: 1 November 2020; Accepted: 17 December 2020; Published: 21 December 2020 Abstract: There are two well-characterized cannabinoid receptors (CB1R and CB2R and other candidates): the central nervous system (CNS) enriched CB1R and peripheral tissue enriched CB2R with a wide dynamic range of expression levels in different cell types of human tissues. Hepatocytes and neurons express low baseline CB1R and CB2R, respectively, and their cell-type-specific functions are not well defined. Here we report inducible expression of CB1R in the liver by high-fat and high sugar diet and CB2R in cortical neurons by methamphetamine. While there is less controversy about hepatocyte CB1R, the presence of functional neuronal CB2R is still debated to date.
    [Show full text]
  • A Novel Phytocannabinoid Isolated from Cannabis Sativa L. with an in Vivo Cannabimimetic Activity Higher Than Δ9-Tetrahydrocann
    www.nature.com/scientificreports OPEN A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol Cinzia Citti1,2,3,6, Pasquale Linciano3,6, Fabiana Russo3, Livio Luongo4, Monica Iannotta4, Sabatino Maione4, Aldo Laganà2,5, Anna Laura Capriotti5, Flavio Forni3, Maria Angela Vandelli3, Giuseppe Gigli2 & Giuseppe Cannazza 2,3* (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain infuences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC itself. In the attempt to defne the phytocannabinoids profle that characterizes a medicinal cannabis variety, a new phytocannabinoid with the same structure of Δ9-THC but with a seven-term alkyl side chain was identifed. The natural compound was isolated and fully characterized and its stereochemical confguration was assigned by match with the same compound obtained by a stereoselective synthesis. This new phytocannabinoid has been called (-)-trans-Δ9-tetrahydrocannabiphorol (Δ9-THCP). Along with Δ9-THCP, the corresponding cannabidiol (CBD) homolog with seven-term side alkyl chain (CBDP) was also isolated and unambiguously identifed by match with its synthetic counterpart. The binding activity of Δ9-THCP against human CB1 receptor in vitro (Ki = 1.2 nM) resulted similar to that of CP55940 (Ki = 0.9 nM), a 9 potent full CB1 agonist. In the cannabinoid tetrad pharmacological test, Δ -THCP induced hypomotility, analgesia, catalepsy and decreased rectal temperature indicating a THC-like cannabimimetic activity.
    [Show full text]
  • Targeting the Endocannabinoid Metabolic Enzymes to Reduce Inflammatory Pain
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2014 Targeting the Endocannabinoid Metabolic Enzymes to Reduce Inflammatory Pain Sudeshna Ghosh Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/3305 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Targeting the Endocannabinoid Metabolic Enzymes to Reduce Inflammatory Pain A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. By Sudeshna Ghosh 01/13/2014 Director: Dr. Aron H. Lichtman, Professor, Pharmacology & Toxicology Virginia Commonwealth University, Richmond, Virginia Acknowledgement My most sincere thanks go to my advisor Dr. Aron Lichtman. I thank him for introducing me to the wonders and challenges of scientific research. I would also like to thank him for allowing me to work under his guidance. He has been a great influence in this project and the direction the research has taken. He is one of the best examples of an ideal mentor who is always ready to listen, understand the needs of the students, and offer all possible help. Additionally, I would like to thank Dr. Laura Wise for her patience, guidance, encouragement, and support during the development of this project. I am indebted to her for believing in me and giving me the support to achieve my goals.
    [Show full text]